| Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference |
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. |
globenewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma |
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences. |
globenewswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs |
Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data |
globenewswire.com |
2025-04-28 20:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets |
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour |
globenewswire.com |
2025-04-25 17:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential |
FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. |
seekingalpha.com |
2025-04-17 21:07:34 |
Czytaj oryginał (ang.) |
| Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions |
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount received under the 2019 collaboration agreement to $135 million Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the IRAK4 degrader program as well as potential future royalties and retains an option to co-develop and co-detail in the United States with the parties splitting U.S. profits and losses SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared the IND for the IRAK4 degrader GS-6791/NX-0479, enabling the initiation of a Phase 1 trial, which is anticipated to begin in Q2 2025. “GS-6791/NX-0479 is a highly optimized, selective, oral degrader of IRAK4, a master regulator of IL-1R/TLR signaling pathways that plays a crucial role in inflammatory processes. |
globenewswire.com |
2025-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on April 8, 2025, the company granted inducement awards to sixteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-11 20:01:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates |
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2025-04-08 22:10:31 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update |
NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with Sanofi Enhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officer Well capitalized with cash and marketable securities of $549.7 million |
globenewswire.com |
2025-04-08 20:00:00 |
Czytaj oryginał (ang.) |
| NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program |
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases. |
zacks.com |
2025-04-03 14:10:41 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-02 15:00:38 |
Czytaj oryginał (ang.) |
| Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases |
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and losses SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that Sanofi has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases. The undisclosed target is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program. |
globenewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting |
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting, which will be held from April 25-30, 2025, in Chicago, IL. |
globenewswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia |
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia (WM). Bexobrutideg is an orally bioavailable, brain penetrant degrader of BTK which is being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. |
globenewswire.com |
2025-03-17 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on March 11, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-14 18:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch. |
Dr. Baynes has been a member of Nurix's Medical Advisory Board since 2023 Dr. Baynes has been a member of Nurix's Medical Advisory Board since 2023 |
globenewswire.com |
2025-03-13 18:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in Upcoming Investor Conferences |
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-14 18:01:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 12:40 p.m. ET. |
globenewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates |
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.77 per share a year ago. |
zacks.com |
2025-01-28 20:11:07 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update |
R eported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66 th American Society of Hematology Annual Meeting |
globenewswire.com |
2025-01-28 18:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer |
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib |
globenewswire.com |
2025-01-22 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation |
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation |
seekingalpha.com |
2025-01-09 10:44:52 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco. |
globenewswire.com |
2025-01-06 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia |
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia |
globenewswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting |
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments |
globenewswire.com |
2024-12-09 20:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting |
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, December 9, 2024. |
globenewswire.com |
2024-12-02 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City. |
globenewswire.com |
2024-11-25 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia |
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation |
globenewswire.com |
2024-11-20 18:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 |
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases |
globenewswire.com |
2024-11-17 12:30:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in Upcoming Investor Conferences |
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November: |
globenewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit |
Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program |
globenewswire.com |
2024-10-21 20:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia |
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial |
globenewswire.com |
2024-10-19 12:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur |
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. |
globenewswire.com |
2024-10-16 20:35:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates |
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. |
zacks.com |
2024-10-11 22:10:18 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update |
Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA |
globenewswire.com |
2024-10-11 20:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology |
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix's proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in collaboration with Gilead Sciences and also in IND-enabling studies, in two posters at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C. |
globenewswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix: An Attractive Early-Stage Biotech Play |
Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. |
seekingalpha.com |
2024-10-08 14:58:22 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics Announces Presentations at Discovery on Target Conference |
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 – October 3, 2024, in Boston, MA. |
globenewswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit |
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024. |
globenewswire.com |
2024-09-06 11:00:00 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data |
Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. |
seekingalpha.com |
2024-09-04 15:59:52 |
Czytaj oryginał (ang.) |
| Nurix Therapeutics to Participate in Upcoming Investor Conferences |
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September: |
globenewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27% |
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-07-25 14:56:10 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice |
Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-07-16 17:05:46 |
Czytaj oryginał (ang.) |